Antithrombin III Monitoring Enters the Conversation in Extracorporeal Carbon Dioxide Removal
Extracorporeal carbon dioxide removal places blood in constant contact with foreign surfaces, and that exposure keeps coagulation at the center of bedside decision-making. The reply to Wang et al. argues for adding antithrombin III monitoring to the surveillance framework used during extracorporeal carbon dioxide removal, a move aimed at complementing what clinicians already watch when clotting risk rises in circuit-based support.
The proposal is clinically logical. Antithrombin III is one of the body’s main endogenous anticoagulant proteins, and when its activity falls, the balance between clot suppression and thrombin generation shifts toward thrombosis. In a patient attached to an extracorporeal circuit, that shift matters immediately because clot formation can shorten circuit life, disrupt gas exchange support, and force exchanges or interruptions that add complexity to already fragile care.
Why Coagulation Monitoring Matters in Circuit-Based Respiratory Support
Extracorporeal support devices are not passive plumbing. Blood moving through tubing, pumps, and artificial membranes is exposed to shear stress and nonphysiologic surfaces, and the hemostatic system responds within minutes. Platelet activation, contact pathway stimulation, and consumption of natural anticoagulants can all contribute to circuit clotting, even when the patient is receiving anticoagulation.
Monitoring only one part of that system can leave clinicians with an incomplete picture. Standard laboratory tests may describe the anticoagulant effect being delivered, but they do not always reveal whether the patient’s endogenous reserve is disappearing at the same time. Antithrombin III sits at that interface. When levels drop, the body becomes less responsive to heparin-based strategies, and anticoagulation may appear less effective than expected despite escalating treatment.
This is the practical appeal of the recommendation. Adding antithrombin III to the monitoring set does not replace existing assessments; it strengthens them. A circuit can fail because the anticoagulant dose is too low, because the inflammatory and prothrombotic milieu is too intense, or because the patient’s own inhibitory pathways are depleted. Distinguishing among those possibilities is what makes a monitoring strategy useful at the bedside.
A Single Biomarker Will Not Solve a Multisystem Problem
Antithrombin III is not a magic key, and no responsible clinician would treat it as one. The coagulation environment in extracorporeal support is shaped by inflammation, illness severity, organ dysfunction, and the mechanical features of the circuit itself. A low antithrombin III level may be a marker of consumption, reduced synthesis, or broader critical illness physiology rather than an isolated actionable abnormality.
Still, the biomarker has a clear physiologic role. Heparin exerts its anticoagulant effect largely by accelerating antithrombin activity, so when antithrombin is depleted, the expected pharmacologic response can weaken. In that setting, a patient may look as though they require more anticoagulation when the deeper problem is biologic resistance to the agent being used. Recognizing that pattern can influence dose adjustment, laboratory interpretation, and the threshold for reassessing the circuit strategy.
One sentence captures the bedside consequence: a falling antithrombin III level can make routine anticoagulation look ineffective long before the circuit clots.
What the Reply Adds to the Clinical Discussion
As a reply to Wang et al., this piece functions as a refinement rather than a challenge. It expands the monitoring frame around extracorporeal carbon dioxide removal by arguing that the anticoagulation picture is incomplete without attention to antithrombin III. The emphasis is on complementarity: conventional surveillance can show what is happening in the circuit, while antithrombin III can help explain why the anticoagulant response is not matching expectations.
That approach fits the way extracorporeal therapies are actually managed. Clinicians rarely make decisions from a single datapoint. They look at circuit pressures, visible clot burden, gas exchange performance, bleeding risk, and the patient’s broader physiologic state. A biomarker that informs endogenous anticoagulant capacity belongs in that same conversation, especially when clotting threatens the durability of a device that is already being used for a narrow and highly technical indication.
The reply also reinforces a broader principle in critical care: coagulation management during extracorporeal therapy is dynamic, not static. A patient who was stable yesterday may have a different anticoagulant requirement today because antithrombin is consumed, inflammation has intensified, or organ function has shifted. Serial measurement makes more sense than a one-time check when the clinical question is whether the system is drifting toward failure.
Bedside Consequences for Extracorporeal Carbon Dioxide Removal
For intensivists, the appeal of antithrombin III monitoring lies in its potential to make anticoagulation more intelligible. If a circuit begins to clot, the question is not only how much anticoagulant is being delivered, but whether the patient can respond to it at all. If antithrombin III is low, escalating heparin may deliver diminishing returns. If the level is preserved, the team may look elsewhere for the explanation, including device factors or other prothrombotic drivers.
The monitoring concept also has implications for bleeding risk. Any attempt to intensify anticoagulation in response to suspected circuit dysfunction increases the possibility of hemorrhagic harm, particularly in critically ill patients who may already have thrombocytopenia, invasive lines, or competing organ failures. Better physiologic targeting may prevent unnecessary dose escalation and reduce the chance of treating the wrong problem.
Short, targeted monitoring can be more actionable than broad empiricism. In extracorporeal carbon dioxide removal, the margin for error is small, and the circuit does not tolerate ambiguity for long.
Why This Matters Even Without New Trial Data in the Reply
This is not a trial report and does not introduce outcome data, enrollment numbers, or comparative endpoints. Its value sits in the clinical logic of the argument itself. By recommending antithrombin III monitoring, the authors sharpen the discussion around anticoagulation adequacy in extracorporeal carbon dioxide removal and point toward a more individualized approach to circuit management.
The remaining question is not whether coagulation deserves attention — it clearly does — but how best to integrate additional biomarkers into routine practice without creating noise. The answer will depend on whether antithrombin III measurement improves interpretation enough to change management, preserve circuit function, or reduce complications in a way clinicians can trust. Until then, the reply serves as a concise reminder that extracorporeal support is as much a hemostatic problem as it is a respiratory one.